Interventions for the treatment of borderline ovarian tumours.
BACKGROUND
The safety of conservative surgery and the benefit of additional interventions after surgery for borderline ovarian tumours are unknown.


OBJECTIVE
To evaluate the benefits and harm of different treatment modalities offered for borderline ovarian tumours.


METHODS
We searched the Cochrane Gynaecological Cancer Group Trials Register to 2009, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE and EMBASE to 2009. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies.


METHODS
Randomised controlled trials (RCTs) that compared different interventions in adult women diagnosed with borderline ovarian tumours of any histological variant.


METHODS
Two review authors independently abstracted data and assessed risk of bias.


RESULTS
We identified seven RCTs that enrolled 372 women. We could not pool results of trials as the treatment comparisons differed.Six RCTs (n = 340) conducted over 15 years ago, evaluated adjuvant therapy (chemotherapy, pelvic external irradiation or intra-peritoneal radioactive isotope therapy) after radical surgery; over 87% of participants had Stage I tumours. Most participants were followed up for over 10 years. Overall and recurrence-free survival were similar between both arms of these trials, except that one trial (n = 66) showed a significantly lower survival (P = 0.03) in women who received chemotherapy (thio-TEPA). Adverse effects of treatment were incompletely reported and all six trials were at high risk of bias.One further trial (n = 32) that recruited participants with bilateral serous tumours who were wishing fertility preservation, revealed a significantly increased chance of pregnancy (hazard ratio (HR) = 3.3, 95% CI 1.4 to 8.0) but non-significantly earlier disease recurrence (HR = 1.5, 95% CI 0.6 to 3.8) in the women who had ultra-conservative surgery (bilateral cystectomy) than in those who had conservative surgery (cystectomy and contralateral oophorectomy). This trial was at low risk of bias.Quality of life (QoL) was not documented in any included trial. We did not find any trials that compared radical with conservative surgery or laparoscopy with laparotomy.


CONCLUSIONS
We did not find evidence to support the use of any specific type of adjuvant therapy for borderline ovarian tumours. RCTs evaluating the benefit of adjuvant therapy with optimally dosed chemotherapy and newer targeted drugs are necessary, particularly for advanced borderline ovarian tumours. The low mortality from borderline ovarian tumours should make recurrence-free survival, time to recurrence and morbidity important end points in such trials.Bilateral cystectomy may be offered to women with bilateral borderline ovarian tumours diagnosed intra-operatively who are wishing to preserve their fertility. Similarly, women who had RCTs comparing radical with conservative surgery and comparing laparoscopy with laparotomy are needed.
Faluyi
Olusola
O
Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh, Scotland, UK, EH4 2XU.
Mackean
Melanie
M
Gourley
Charlie
C
Bryant
Andrew
A
Dickinson
Heather O
HO
D000328:Adult; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011247:Pregnancy; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic
Cancer. 1992 Feb 1;69(3):741-9
1730124
J Natl Cancer Inst. 2003 Jan 15;95(2):113-25
12529344
J Clin Oncol. 2000 Jan;18(1):106-15
10623700
J Natl Cancer Inst. 2003 Jan 15;95(2):125-32
12529345
Lancet. 2002 Aug 17;360(9332):505-15
12241653
Gynecol Oncol. 2006 May;101(2):255-60
16307793
Fertil Steril. 2001 Jan;75(1):92-6
11163822
Stat Med. 1998 Dec 30;17(24):2815-34
9921604
Obstet Gynecol. 1982 Jan;59(1):93-6
7078855
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
J Natl Cancer Inst. 2008 Mar 19;100(6):399-406
18334710
Hum Reprod. 2007 Feb;22(2):578-85
17050549
Cancer. 1986 Nov 1;58(9):2052-65
3756820
Int J Gynecol Pathol. 1993 Apr;12(2):120-7
8463035
Am J Obstet Gynecol. 1977 Jul 15;128(6):617-25
406788
Lancet Oncol. 2009 Apr;10(4):327-40
19282241
BMJ. 2010 Mar 23;340:c332
20332509
Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):3-7
17983919
Obstet Gynecol. 2002 Jan;99(1):3-10
11777502
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):201-7
12909234
J Clin Oncol. 2007 Jul 10;25(20):2928-37
17617524
Cancer. 2002 Dec 1;95(11):2380-9
12436446
Hum Reprod. 2010 Aug;25(8):1966-72
20573679
Mod Pathol. 2005 Feb;18 Suppl 2:S33-50
15761465
Gynecol Oncol. 1992 Nov;47(2):150-8
1468692
Cancer. 2003 May 15;97(10 Suppl):2631-42
12733128
Am J Surg Pathol. 2006 Nov;30(11):1367-71
17063075
Int J Gynecol Cancer. 2007 Mar-Apr;17(2):342-9
17343573
Curr Opin Obstet Gynecol. 2003 Feb;15(1):39-43
12544500
Br J Obstet Gynaecol. 1998 Nov;105(11):1136-47
9853761
Fertil Steril. 2005 Feb;83(2):284-90; quiz 525-6
15705364
Gynecol Oncol. 1993 Nov;51(2):236-43
8276300
Gynecol Oncol. 1991 Jun;41(3):230-3
1869100
J Clin Epidemiol. 1997 Jun;50(6):683-91
9250266
Br J Cancer. 1995 Aug;72(2):511-8
7640241
Gynecol Oncol. 1996 Feb;60(2):301-7
8631556
Adv Anat Pathol. 1999 Sep;6(5):247-74
10472378
Clin Cancer Res. 2007 Jun 15;13(12):3617-22
17575226
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Am J Obstet Gynecol. 1988 Nov;159(5):1088-94
3189441
Gynecol Oncol. 1990 Jul;38(1):90-8
2162318
N Engl J Med. 1990 Apr 12;322(15):1021-7
2181310
Acta Obstet Gynecol Scand. 2007;86(5):620-6
17464594
Cancer. 1996 Nov 15;78(10):2236-46
8918420
BMJ. 2003 Sep 6;327(7414):557-60
12958120